Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy

Key Points

• The aim is to evaluate how ASXL1 mutations influence survival outcomes in acute myeloid leukemia (AML) patients treated with lower intensity therapy.
• Retrospective analysis of 554 adults with newly diagnosed acute myeloid leukemia treated with lower intensity therapy.
• Subjects were stratified based on ASXL1 mutation status and treatment backbone.
• ASXL1 mutations were independently associated with inferior overall survival in patients.
• The classification of AML as intermediate risk may be affected by the specific lower intensity therapy used.

Abstract